Coupe N, Schadendorf D, Danson S, et al. PACMEL: A randomised phase 2 study of paclitaxel with or without trametinib or pazopanib in Advanced BRAF wild type melanoma. SMR 2017, abstract SMR05-2.
Synergetisch effect van radiotherapie + immuuntherapie bij NSCLC
mei 2021 | Immuuntherapie, Longoncologie, Radiotherapie